Metabolic diseases in Orthopaedics- Rickets, Osteomalacia and Scurvy
1. SCURVY
Scurvy is disease caused by severe Vitamin C deficiency which presents with
joint effusions, swelling over long bones, bleeding gums, loosening of teeth,
hematuria, and susceptibility to hemorrhage.
Diagnosis is made based on history, clinical and radiological picture, and
resolution of symptoms following vitamin C administration. Lab tests are
usually not helpful.
Treatment is prompt administration of Vitamin C.
2. RISK FACTORS
elderly, especially men who live alone
chronic malnutrition
overcooking destroys vitamin C
alcoholic
smokers
malabsorptive conditions (Whipple's disease, inflammatory bowel disease, cancer chemotherapy)
PATHOPHYSIOLOGY
humans are unable to synthesize L-ascorbic acid because the enzyme L-gluconolactone oxidase is
nonfunctional
Vitamin C deficiency leads to decrease in chondroitin sulfate and collagen synthesis and repair
impaired intracellular hydroxylation of collagen peptides
net effect is altered bone formatin with the greatest effect occuring in the metaphysis
defect in spongiosa of the metaphysis at the growth plate
3. PRESENTATION
History
infant diet consisting of evaporated or condensed milk
"tea and toast" diet in elderly
Symptoms
malaise and fatigue
pain
bone pain
myalgia, because of reduced carnitine production
gum bleeding and loosening of teeth
hematuria
hematemesis
hemorrhage
iron deficiency
4. PHYSICAL EXAM
petechiae and ecchymosis
joint effusions
swelling over long bones because of subperiosteal hemorrhage
scorbutic rosary (costochondral separation)
o angular step-off deformity in children
o differentiated from rachitic rosary, which is rounded and nodular
5. IMAGING
RADIOGRAPHS – wrist , knee, sternal ends of ribs
FINDINGS
the white line of Frankel
widened zone of provisional calcification
between epiphysis and metaphysis
Trummerfeld zone
transvese radiolucent band in the metaphysis adjacent to
the Frankel line also known as the scurvy line
Wimberger ring
ring of increased density surrounding epiphysis
Pelkin spur and fracture
metaphyseal spurs and fractures
corner sign of Park
metaphyseal clefts
thin cortices ("pencil-point" cortex)
decreased trabeculae with ground-glass osteopenia
subperiosteal elevation
epiphyseal separation
fractures and dislocations
6. TREATMENT
Non-operative
vitamin C replacement
oral vitamin C at 250mg qid x 1 week in adults
Indications
signs and symptoms of scurvy
chronic malnutrition
7. RICKETS
Rickets is a metabolic bone disease caused by a defect in mineralization of
osteoid matrix caused by inadequate calcium and phosphate that occurs prior
to closure of the physis. Patients present with characteristic features such as
bowing of long bones, ligamentous laxity, brittle bones and enlargement of
costal cartilage.
Diagnosis is made based on a thorough evaluation of serum labs, clinical
features, and radiographic findings.
Treatment involves medical management to resolve the underlying etiology
of rickets.
8. Pathophysiology
Vitamin D and PTH play an important role in calcium homeostasis
disruption of calcium/phosphate homeostasis
poor calcification of cartilage matrix of growing long bones
occurs at zone of provisional calcification
leads to increased physeal width and cortical thinning/bowing
orthopaedic manifestations include-
brittle bones with physeal cupping/widening
bowing of long bones
ligamentous laxity
flattening of skull
enlargement of costal cartilage (rachitic rosary)
kyphosis (cat back)
10. IMAGING
RADIOGRAPHS- AP and lateral of affected bone
FINDINGS
physeal widening
metaphyseal cupping
decreased bone density
Looser's zones
pseudofracture on the compression side of bone
rachitic rosary
prominence of rib heads at the osteochondral junction
lower extremity bowing
often genu varum
codfish vertebrae
cat back
dorsal kyphosis
11. CLASSIFICATION
Vitamin D-resistant (familial hypophosphatemic)
most common form of heritable rickets
presents at 1-2 years of age
caused by inability of renal tubules to absorb phosphate
GFR is normal
vitamin D3 response is impaired
Genetics
X-linked dominant
most common form
results from mutation in PHEX gene
leads to increased levels of FGF23, which decreases renal phosphate absorption and suppresses
renal 25-(OH)-1α-hydroxylase activity
autosomal dominant
results from mutation in FGF23
leads to decreased FGF23 degradation
autosomal recessive
results from mutation in dentin matrix protein 1 (DMP1) gene
leads to impaired osteocyte maturation and bone mineralization, and increased levels of FGF23
12. Vitamin D-deficient (nutritional)
results from decreased dietary intake of Vitamin D
rare now that Vitamin D is added to milk
presents at 6 months - 3 years of age
risk factors
premature infants
black children > 6 months who are still breastfed
patients with malabsorption syndromes (celiac sprue) or chronic parenteral nutrition
Asian immigrants
patients with unusual dietary choices (vegetarian diet)
pathophysiology
low Vitamin D levels lead to decreased intestinal absorption of calcium
low calcium levels leads to a compensatory increase in PTH and bone resorption
bone resorption leads to increased alkaline phosphatase levels
Vitamin D-dependent (type I & type II)
rare disorder
leads to clinical features similar to Vitamin D-deficient rickets but more severe
13. clinical characteristics
type I
hypotonia, muscle weakness, growth failure, hypocalcemic seizures, joint pain/deformity,
fractures in early infancy
type II
hypotonia, muscle weakness, growth failure, hypocalcemic seizures, growth retardation, bone
pain, severe dental caries or dental hypoplasia
pathophysiology
type I
results from autosomal recessive mutation in renal 25-(OH)-1α-hydroxylase
responsible gene 12q14
prevents conversion of inactive form of vitamin D to active form
leads to decreased calcitriol
type II
results from autosomal recessive mutation in intracellular receptor for 1,25-(OH)2-vit. D
leads to increased calcitriol
14. TREATMENT
NON-OPERATIVE
calcitriol
Indications
Vitamin D-resistant (familial hypophosphatemic) rickets
type I Vitamin D-dependent rickets
phosphate replacement
Indication - Vitamin D-resistant (familial hypophosphatemic) rickets
Vitamin D
Indications
Vitamin D-deficient (nutritional) rickets
type II Vitamin D-dependent rickets (partial 1,25-(OH)2-vitamin D resistance)
Calcium
Indication- type II Vitamin D-dependent rickets (total 1,25-(OH)2-vitamin D resistance)
Burosumab
human monoclonal antibody to FGF-23
approved for the treatment of X-linked hypophosphatemia among children 1 year and older.
15. DOSES
•Calcitriol
•20-30 μg/kg/day split into 2-3 doses in children
•0.5-0.75 μg/day split into 2 doses in adults
•Phosphate replacement
•20-40 mg/kg/day split into 3-5 doses in children
•750-1000 mg/day split into 3-4 doses in adults
•Must be given in combination with active vitamin D (i.e. calcitriol) in XLH patients, as this prevents the
development of secondary hyperparathyroidism as seen in patients treated with phosphate salts alone
•Vitamin D
•5000 IU/day for 6-10 weeks
OPERATIVE
•corrective surgery (multilevel osteotomy)
indications
•severe tibial bowing
technique
•variety of fixation devices including K-wires, plates, intramedullary nails, and/or external fixation
16. OSTEOMALACIA
Osteomalacia is a metabolic bone disease where defective mineralization
results in a large amount or unmineralized osteoid.
Diagnosis is made based on a thorough evaluation of serum labs, clinical
features, and radiographic findings.
Treatment involves medical management with Vitamin D supplementation
and resolving the underlying etiology.
18. PRESENTATION
Symptoms
generalized bone and muscle pain
fractures of long bones, ribs and vertebrae
proximal muscle weakness weakness
Fatigue
Physical exam
waddling gait
from hip pain and thigh weakness
difficulty rising from chair and climbing stairs
19. IMAGING
RADIOGRAPHS FINDINGS
Looser's zones (insufficiency fractures)
o medial femoral cortex
o pubic ramus
o scapula
fractures (especially in the proximal femur/femoral neck)
biconcave vertebral bodies
trefoil pelvis
protrusio acetabuli
BONE SCAN
increased activity
20. TREATMENT
Nonoperative
large doses of oral vitamin D (1000IU/day), treat underlying cause
specific subgroups of patients
on long-term anticonvulsant therapy
supplement with 400-800IU/day of vitamin D
with hepatobiliary disease
supplement with 25(OH)-vit D
with renal disease
supplement with 1,25(OH)2 vit D
21. SERUM
CALCIUM
SERUM
PHOSPHAT
E
ALKALINE
PHOSPHATE
PTH 25 (OH) VIT
D
1, 25 (OH)
VIT D
URINARY
CALCIUM
OSTEOMALACIA LOW LOW HIGH HIGH LOW LOW LOW
OSTEOPOROSIS NORMAL NORMAL VARIABLE NORMAL NORMAL NORMAL NORMAL
TUMOR INDUCED
OSTEOMALACIA
LOW VERY LOW LOW LOW LOW LOW LOW
OSTEOPETROSIS NORMAL NORMAL HIGH NORMAL NORMAL NORMAL NORMAL